Phase 2Recruiting
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
An Open Label Phase II Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma
- Sponsor
- Inova Health Care Services (Academic or other)
- Enrolment
- 19 planned
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Memantine Hydrochloride; Bevacizumab; Atezolizumab
- Ages
- adults, older adults
- Registry
- NCT06789757
Full record on ClinicalTrials.gov
From the registry
The purpose of this research is to see the effect of triplet therapy with atezolizumab, bevacizumab, and memantine in treatment of your hepatocellular carcinoma.
Primary outcomes
- Objective response rate (ORR) of patients who are treated with the combination of atezolizumab, bevacizumab, and memantine.
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered